Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

CooperVision, a segment of The Cooper Companies (COO - Analyst Report), a company dedicated to contact lens and women’s health, recently revealed that the Food and Drug Administration (“FDA”) has granted a Special 510 (k) for its Avaira Toric silicone hydrogel bi-weekly contact lenses to correct astigmatism.

The company will shortly re-launch the Avaira Toric lenses. Its lenses provide a comfortable fit for a wide range of powers. Other features include its superior ballast architecture and the Aquaform Comfort Science, which allows the lens material to maintain moisture. These contact lenses illustrate the company’s determination to ensure that eye care specialists have as many choices as possible when dispensing lenses.

Cooper, a global medical products company, specializes in a wide range of contact lenses for the vision correction market with a smaller strategic business unit for women’s health. It reportedly holds the number three position in the $6 billion global contact lens industry.

The company is a leader in the high-margin toric lens market. It offers multiple designs of toric lenses, across a wide range of parameters, unlike some of its competitors, who offer toric lenses in a limited number of designs. Cooper is benefiting from strong demand for its Biofinity toric lenses.

However, Cooper faces formidable competition in each of its major product lines. Competition comes from well established global contact lens makers such as Johnson & Johnson (JNJ - Analyst Report) and Novartis (NVS - Snapshot Report). Depressed levels of consumer spending have heightened the company’s competitive pressures. We currently have a Neutral recommendation on Cooper. The stock currently retains a Zacks #2 Rank, which translates into a short-term “Buy” recommendation.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 24.83 +14.85%
BITAUTO HOLD BITA 35.20 +14.40%
E HOUSECHINA EJ 10.98 +9.15%
CANADIAN SOL CSIQ 27.02 +7.34%
KNIGHTSBRIDG VLCCF 12.46 +5.41%